ClinicalTrials.gg
Sign In
RecruitingNCT06645977RESPIRAREUpdated Oct 17, 2024

Patients With Interstitial Lung Disease

An observational study in Interstitial Lung Disease, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 6 months later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Study summary

Prospective monocentric collection of data from adult patients with interstitial lung disease (ILD), to provide real-world data on current patient management at the ILD clinic.

02

Conditions studied

  • Interstitial Lung Disease
03

In context

Lung Diseases, Interstitial

656 studies on the registry are indexed under Lung Diseases, Interstitial; 241 are open to participants now.

This study's planned enrollment of 1,200 is above the median of 150 across 273 observational studies indexed under Lung Diseases, Interstitial.

Browse Lung Diseases, Interstitial studies →

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 948 studies on the registry; 537 are open to participants now.

Browse Fondazione Policlinico Universitario Agostino Gemelli IRCCS studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed with interstitial lung disease from ILD clinic of the Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years
  • Diagnosis of ILD, according to international guidelines.

Exclusion criteria

Exclusion Criteria:

  • Inability to give informed consent.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Prevalce ILD

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2025, 12 months after the start.

Of 115 non-industry observational studies under Lung Diseases, Interstitial, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 274. This study's planned 12 months is below that.

Counting every sponsor, half of 132 studies reached it within 56 months; a quarter within 29 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2024
First posted
Oct 17, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Apr 4, 2025
CompletionEst.
Apr 4, 2025
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06645977
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Responsible party
RICHELDI LUCA (Professor, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) — Principal investigator
First posted
Oct 17, 2024
Start date
Apr 1, 2024
Primary completion
Apr 4, 2025 (estimated)
Completion
Apr 4, 2025 (estimated)
Last update
Oct 17, 2024

Study contacts

Luca Richeldi
Contact
luca.richeldi@policlinicogemelli.it
0630157857

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lung Diseases, Interstitial →

Other studies from this sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS →

Start the discussion